Adastra Submits Medical Sales License Application And Engages IR Labs To Provide Investor Relations Services

Adastra Holdings Ltd. XTXXF XTRX D submitted medical sales license application to Health Canada on April 1, 2022.

A medical sales license would permit Adastra to perform the following activities:

  • Sell cannabis extracts to medical cannabis patients and licensed health practitioners;

  • Develop products classified as cannabis extracts:

    • Inhaled (vaporizer cartridge and shatter),

    • Ingested (tincture, oil, capsule, soft gel and oral spray),

    • Other (suppository);

  • Sell dried cannabis

"I am particularly excited about the future of cannabinoid-based medical treatments, especially the pharmaceutical distribution of these remedies," stated Michael Forbes, CEO, corporate secretary and director of Adastra. "Having strong ties to the medical community, I am confident that CBD, CBN and CBG specifically will play a significant role in the Canadian medical market in the near future. Adastra's ability to sell to the growing and established medical market positions the company to leverage its existing clinics for direct-to-patient sales and pharmacy sales soon. We are also uniquely positioned to tap into my pharmacy retail network in order to provide Adastra's medical cannabinoid products to patients across Canada."

Engagement with irlabs

Adastra has entered into an engagement letter dated effective April 8, 2022 with IR Labs Inc., whereby irlabs has agreed to provide the company with certain investor relations services in the areas of:

  • capital markets advisory, including strategic advisory and introductions to investors and investment bankers

  • the development and management of an investor relations and communications program, including public relations/media, social media and stakeholder relations

Either party may terminate the agreement at any time by providing the other party with 30 days' prior written notice of termination. In consideration for the services, the company has agreed to pay irlabs a monthly fee of $10,000 in cash, plus applicable taxes, due and payable on the last day of each month. The first payment will be $15,000 in cash, plus applicable taxes, due and payable on April 30, 2022. The company has also agreed to reimburse irlabs for all reasonable out-of-pocket expenses incurred in connection with irlabs performing the services. In addition, irlabs will bill a monthly charge totalling 3% of the Monthly Fee to cover subscription fees for market intelligence platforms, media monitoring, certain information retrieval services, and other ordinary course items that will not be billed to the company on an itemized basis. irlabs has agreed not to incur any aggregate disbursements greater than $500 a month without the company's approval.

Photo: Courtesy of CNW Group/Adastra Holdings Ltd.

Related News

Adastra Holdings Approved For Dealer's License For Psilocybin, Psilocin, MDMA, DMT, 5-MeO-DMT & LSD


 

Posted In: IR Labs IncMichael ForbesCannabisNewsMarkets

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.